These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1815971)

  • 41. Intranasal absorption of melatonin in vivo bioavailability study.
    Bechgaard E; Lindhardt K; Martinsen L
    Int J Pharm; 1999 May; 182(1):1-5. PubMed ID: 10332069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic behavior of peramivir in the plasma and lungs of rats after trans-nasal aerosol inhalation and intravenous injection.
    Ding H; Wu S; Dai X; Gao Y; Niu Y; Fang N; Song Y; Zhang M; Wang X; Chen T; Zhang G; Wu J; Li Y; Han J
    Biomed Pharmacother; 2020 Sep; 129():110464. PubMed ID: 32768954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers.
    Perkins KA; Lerman C; Keenan J; Fonte C; Coddington S
    Nicotine Tob Res; 2004 Jun; 6(3):501-7. PubMed ID: 15203784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The bioavailability of intranasal and smoked methamphetamine.
    Harris DS; Boxenbaum H; Everhart ET; Sequeira G; Mendelson JE; Jones RT
    Clin Pharmacol Ther; 2003 Nov; 74(5):475-86. PubMed ID: 14586388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma nicotine pharmacokinetics in dogs after intravenous administration: determination by radioimmunoassay.
    Monji N; Castro A
    Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):267-77. PubMed ID: 461952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nicotine absorption after pulmonary instillation.
    Herrmann DR; Olsen KM; Hiller FC
    J Pharm Sci; 1992 Nov; 81(11):1055-8. PubMed ID: 1447703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
    Zhu T; Ansquer JC; Kelly MT; Sleep DJ; Pradhan RS
    J Clin Pharmacol; 2010 Aug; 50(8):914-21. PubMed ID: 20145261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine.
    Fattinger K; Benowitz NL; Jones RT; Verotta D
    Eur J Clin Pharmacol; 2000 Jul; 56(4):305-10. PubMed ID: 10954344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prolonged delivery of nicotine in rats via nasal administration of proliposomes.
    Jung BH; Chung BC; Chung SJ; Lee MH; Shim CK
    J Control Release; 2000 May; 66(1):73-9. PubMed ID: 10708880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability.
    Hussain MA; Aungst BJ; Kapil R; Mousa SA
    J Pharm Sci; 1997 Dec; 86(12):1358-60. PubMed ID: 9423145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.
    Foster D; Upton R; Christrup L; Popper L
    Ann Pharmacother; 2008 Oct; 42(10):1380-7. PubMed ID: 18728103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels.
    Hurt RD; Dale LC; Croghan GA; Croghan IT; Gomez-Dahl LC; Offord KP
    Mayo Clin Proc; 1998 Feb; 73(2):118-25. PubMed ID: 9472993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition, absorption, and biologic response.
    Suman JD; Laube BL; Dalby R
    J Aerosol Med; 2006; 19(4):510-21. PubMed ID: 17196079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The systemic availability of buprenorphine administered by nasal spray.
    Eriksen J; Jensen NH; Kamp-Jensen M; Bjarnø H; Friis P; Brewster D
    J Pharm Pharmacol; 1989 Nov; 41(11):803-5. PubMed ID: 2576057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.
    Ortiz S; Flach S; Caracta C; Gil EG; Jansat JM
    J Clin Pharmacol; 2012 Jun; 52(6):819-27. PubMed ID: 21628603
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist.
    Lundin S; Akerlund M; Fagerström PO; Hauksson A; Melin P
    Acta Endocrinol (Copenh); 1986 Aug; 112(4):465-72. PubMed ID: 3751461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24).
    Wüthrich P; Martenet M; Buri P
    Pharm Res; 1994 Feb; 11(2):278-82. PubMed ID: 8165188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma nicotine concentrations from repeated doses of nasal nicotine solution.
    West RJ; Jarvis MJ; Russell MA; Feyerabend C
    Br J Addict; 1984 Dec; 79(4):443-5. PubMed ID: 6598970
    [No Abstract]   [Full Text] [Related]  

  • 60. Bioavailability of intranasal metoclopramide.
    Ward MJ; Buss DC; Ellershaw J; Nash A; Routledge PA
    Br J Clin Pharmacol; 1989 Nov; 28(5):616-8. PubMed ID: 2590616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.